Quick Takeaways
- BML Investment Partners, L.P. filed SCHEDULE 13G for LAVA Therapeutics N.V. Common shares, par value $0.14 per share (LVTX).
- Disclosed ownership: 7.4%.
- Date of event: 26 Feb 2025.
BML Investment Partners, L.P. - 26 Feb 2025 SCHEDULE 13G Report for LAVA Therapeutics N.V. Common shares, par value $0.14 per share (LVTX)
- Filing Manager
- BML Investment Partners, L.P.
- Reporting Manager
- BML Investment Partners, L.P.
- Symbol
- LVTX
- Shares outstanding
- 26,460,946 shares
- Disclosed Ownership
- 1,958,110 shares
- Ownership
- 7.4%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Mar 2025, 14:03:50 UTC
- Date of event
- 26 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BML Investment Partners, L.P. disclosed 7.4% ownership in LAVA Therapeutics N.V. Common shares, par value $0.14 per share (LVTX) on 26 Feb 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Mar 2025, 14:03.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 7.4% | 1,958,110 | 0 | 1,958,110 | Braden M Leonard | BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member |